Published June 13, 2023 | Version v1

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Description

LAG3 inhibition for treating metastatic or unresectable melanoma has a reduced efficacy in subjects with T2D, possibly due to a low expression of LAG3. Our data suggest that glycemia should be monitored and maintained within control levels in these patients.

Files